AMGN - Amgen Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
191.49
+0.18 (+0.09%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close191.31
Open191.93
Bid0.00 x 800
Ask0.00 x 1000
Day's Range190.92 - 192.73
52 Week Range163.31 - 210.19
Volume1,685,984
Avg. Volume3,276,435
Market Cap119.16B
Beta (3Y Monthly)0.95
PE Ratio (TTM)15.17
EPS (TTM)12.62
Earnings DateApr 22, 2019 - Apr 26, 2019
Forward Dividend & Yield5.80 (3.03%)
Ex-Dividend Date2019-02-14
1y Target Est207.33
Trade prices are not sourced from all markets
  • Markit15 hours ago

    See what the IHS Markit Score report has to say about Amgen Inc.

    Amgen Inc NASDAQ/NGS:AMGNView full report here! Summary * Perception of the company's creditworthiness is neutral * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low Bearish sentimentShort interest | PositiveShort interest is extremely low for AMGN with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting AMGN. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, ETFs holding AMGN are favorable, with net inflows of $14.60 billion. Additionally, the rate of inflows is increasing. Economic sentimentPMI by IHS Markit | NeutralAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however. Credit worthinessCredit default swap | NeutralThe current level displays a neutral indicator. AMGN credit default swap spreads are within the middle of their range for the last three years.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent
    Zacksyesterday

    Regeneron, Sanofi Get EC Nod for Label Expansion of Praluent

    Regeneron (REGN) and partner Sanofi receives approval in Europe for the label expansion of Praluent to reduce cardiovascular (CV) risk in adults with established atherosclerotic CV disease.

  • Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down
    Zacks2 days ago

    Spectrum Pharma (SPPI) Withdraws Rolontis BLA, Shares Down

    Spectrum Pharma (SPPI) withdraws the BLA seeking approval for Rolontis, as the FDA requests for additional manufacturing-related data.

  • Better Buy: Amgen vs. Gilead Sciences
    Motley Fool3 days ago

    Better Buy: Amgen vs. Gilead Sciences

    Which stock wins in a battle between these two big biotechs?

  • TheStreet.com4 days ago

    Stocks Close Up on Signs of Progress in U.S.-China Trade Talks, Boeing Higher

    Stocks close up on Friday amid hopes the U.S. and China are making progress on a trade pact and word that Boeing is speeding up its 737 MAX fixes.

  • Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?
    Investor's Business Daily4 days ago

    Can Amgen Leapfrog A Key Rival And Add Millions Of New Patients?

    Leading biotech Amgen could expand the market for Repatha by 4.5 million patients with high cholesterol if the PCSK9 inhibitor proves its mettle in a new study, an analyst said Friday.

  • Roche Gets Approval for Label Expansion of MabThera in Europe
    Zacks4 days ago

    Roche Gets Approval for Label Expansion of MabThera in Europe

    Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.

  • PR Newswire4 days ago

    Amgen Announces New Four-Year Outcomes Study To Examine Long-Term Effects Of Repatha® (evolocumab) In High-Risk Cardiovascular Disease (CVD) Patients Without Prior Heart Attack Or Stroke

    VESALIUS-CV is the Latest Study in Amgen's PROFICIO Clinical Program Investigating the Impact of Repatha on CVD in Multiple Patient Populations Phase 3 Study Will Enroll High-Risk Patients who Have Significant ...

  • Roche Receives EC Approval for Label Expansion of Hemlibra
    Zacks6 days ago

    Roche Receives EC Approval for Label Expansion of Hemlibra

    Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.

  • Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades
    Investopedia6 days ago

    Blue Chip Drug Stocks Face 'Reckoning' on Future Downgrades

    Shares of major drug makers including Pfizer Inc. (PFE), Eli Lilly & Co. (LLY), Amgen Inc. (AMGN), Novartis AG (NVS) and AbbVie Inc. (ABBV), are already dramatically lagging the broader market this year.

  • FDA medical adviser: 'Congress is owned by pharma'
    Yahoo Finance7 days ago

    FDA medical adviser: 'Congress is owned by pharma'

    Despite many politicians, particularly declared presidential candidates, beginning to speak out against big pharma, an FDA medical adviser does not think that anything will come out of it “because Congress is owned by pharma.”

  • Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval
    Zacks8 days ago

    Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval

    FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.

  • Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer
    Zacks8 days ago

    Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer

    Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.

  • Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk
    PR Newswire8 days ago

    Amgen and Jay Leno Partner to Sound the Alarm on High Cholesterol and its Link to Heart Attack and Stroke in Patients Most at Risk

    THOUSAND OAKS, Calif., March 12, 2019 /PRNewswire/ -- Amgen (AMGN) today launched Cholesterol 911, a national initiative urging high-risk cardiovascular disease patients to reduce their risk of another heart attack or stroke by addressing their continued high LDL-C, or "bad" cholesterol. Comedian and television host Jay Leno has partnered with Amgen to motivate patients and caregivers to get in the driver's seat as it relates to their cholesterol management.

  • Is Amgen (AMGN) a Profitable Pick ForValue Investors Now?
    Zacks9 days ago

    Is Amgen (AMGN) a Profitable Pick ForValue Investors Now?

    Amgen (AMGN) stock may be a good choice for value-oriented investors right now from multiple angles.

  • Better Buy: Amgen vs. Biogen
    Motley Fool9 days ago

    Better Buy: Amgen vs. Biogen

    These cash-flow monsters are trading on the cheap. Which is the better bet for new money today?

  • Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?
    Investor's Business Daily11 days ago

    Could A Patent Battle Force Sanofi To Snap Up This Biotech Stock?

    On Friday an analyst questioned the longevity of a collaboration between Regeneron Pharmaceuticals and Sanofi for a medicine to lower cholesterol that rivals an Amgen drug.

  • What’s Expected to Drive Amgen’s Growth in Fiscal 2019
    Market Realist12 days ago

    What’s Expected to Drive Amgen’s Growth in Fiscal 2019

    Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Financial performance in fiscal 2018 In fiscal 2018, Amgen’s (AMGN) revenue rose 4% YoY (year-over-year) to $23.75 billion, and its non-GAAP EPS rose 14% YoY to $14.40. In

  • PR Newswire12 days ago

    Amgen Announces 2019 Second Quarter Dividend

    THOUSAND OAKS, Calif., March 7, 2019 /PRNewswire/ -- Amgen (AMGN) today announced that its Board of Directors declared a $1.45 per share dividend for the second quarter of 2019. Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

  • PR Newswire12 days ago

    Amgen To Present At The Cowen and Company 39th Annual Healthcare Conference

    THOUSAND OAKS, Calif. , March 7, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Cowen and Company 39 th Annual Healthcare Conference at 9:20 a.m. ET on Tuesday, March 12, 2019 , in Boston ...

  • Amgen’s and Merck’s Capex and Interest Expenses
    Market Realist13 days ago

    Amgen’s and Merck’s Capex and Interest Expenses

    Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Capital expenditureAmgen (AMGN) and Merck (MRK) reported capital expenditure of $738 million and $2.61 billion, respectively, in fiscal 2018. In its fourth-quarter conference

  • Comparing Amgen’s and Merck’s Dividends and Tax Rates
    Market Realist13 days ago

    Comparing Amgen’s and Merck’s Dividends and Tax Rates

    Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Dividend projections Amgen (AMGN) and Merck (MRK) reported dividends per share of $5.28 and $1.99, respectively, in fiscal 2018. In its fourth-quarter conference call, Amgen

  • Amgen or Merck: Which Is Controlling Expenses Better?
    Market Realist13 days ago

    Amgen or Merck: Which Is Controlling Expenses Better?

    Comparing Pharmaceutical Picks: Amgen or Merck?(Continued from Prior Part)Expense guidance for fiscal 2019 In its fourth-quarter conference call, Amgen (AMGN) guided for its operating expenses being flat or lower YoY (year-over-year) in fiscal

  • PR Newswire13 days ago

    New Data From Amgen To Be Presented At ACC.19 Continues To Build Evidence For Repatha® (evolocumab) Across Multiple Patient Populations

    THOUSAND OAKS, Calif., March 6, 2019 /PRNewswire/ -- Amgen (AMGN) today announced the presentation of nine cardiovascular scientific research abstracts, including safety and efficacy results from the largest and longest open label study of homozygous familial hypercholesterolemia (HoFH) patients (TAUSSIG),1  as well as a sub-analysis from the Repatha® (evolocumab) cardiovascular outcomes study (FOURIER). Additional abstracts to be presented include real-world evidence (RWE) findings from the GOULD registry demonstrating suboptimal care for high-risk cardiovascular disease (CVD) patients.2,3 These analyses will be featured at the American College of Cardiology's 68th Annual Scientific Session (ACC.19) in New Orleans, March 16-18, 2019. "The findings we are presenting at ACC.19 further reinforce the growing body of evidence demonstrating how Repatha can safely and effectively lower LDL-C levels in a wide range of patients, such as those with atherosclerotic disease or who have a genetic risk of high cholesterol," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.